CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 97 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,892,400 | +123.2% | 60,000 | +100.0% | 0.27% | +372.4% |
| Q3 2022 | $847,900 | +60.6% | 30,000 | +50.0% | 0.06% | -6.5% |
| Q2 2022 | $528,000 | -72.8% | 20,000 | -64.0% | 0.06% | +14.8% |
| Q1 2022 | $1,943,000 | +558.6% | 55,500 | +455.0% | 0.05% | +500.0% |
| Q3 2021 | $295,000 | – | 10,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,713,470,000 | 41.39% |
| Perceptive Advisors | 6,511,727 | $184,021,000 | 5.34% |
| Finepoint Capital LP | 536,901 | $15,173,000 | 4.99% |
| Artal Group S.A. | 2,000,000 | $56,520,000 | 2.41% |
| Rock Springs Capital Management LP | 2,499,148 | $70,626,000 | 1.82% |
| Ikarian Capital, LLC | 178,100 | $5,033,000 | 1.00% |
| Hood River Capital Management LLC | 896,572 | $25,337,000 | 0.97% |
| Frazier Life Sciences Management, L.P. | 393,000 | $11,106,000 | 0.86% |
| HighVista Strategies LLC | 23,611 | $667,000 | 0.38% |
| FEDERATED HERMES, INC. | 3,313,333 | $93,635,000 | 0.27% |